Why carry out this study?

The clinical burden of type 1 diabetes in Sweden is growing, and novel treatments could help to keep individuals with the disease within glycemic targets and thereby lower the incidence of costly long-term diabetes-related complications.

However, the benefits of novel efficacious interventions must be judged against the costs of introducing such therapies as healthcare budgets come under increasing strain worldwide.

The present study therefore aimed to evaluate the long-term cost-effectiveness of a novel advanced hybrid closed-loop (AHCL) system (the MiniMed 780G system) versus intermittently scanned continuous glucose monitoring (isCGM) plus multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with type 1 diabetes in Sweden.

What was learned from the study?

Outcomes projected over patients’ lifetimes indicated that the MiniMed 780G system was associated with improved life expectancy and quality-adjusted life expectancy and increased costs versus is CGM plus MDI or CSII from a societal perspective in Sweden, resulting in an incremental cost-effectiveness ratio of SEK 373,700 per quality-adjusted life year gained.

Based on long-term projections, the MiniMed 780G system was considered a cost-effective treatment option in people with type 1 diabetes in Sweden.